Market Update: Merck & Co Inc (NYSE:MRK) – Results of Phase 2 Study of Merck’s Investigational Beta-Lactamase Inhibitor Relebactam Presented at ICAAC/ICC 2015

[Business Wire] – Merck , known as MSD outside the United States and Canada, today announced that a Phase 2 study of relebactam, the company’s investigational beta-lactamase inhibitor for the treatment, in combination . . . → Read More: Market Update: Merck & Co Inc (NYSE:MRK) – Results of Phase 2 Study of Merck’s Investigational Beta-Lactamase Inhibitor Relebactam Presented at ICAAC/ICC 2015 Similar Articles: Stock Update (NYSE:MRK): In Interim Results from Phase 3 Study, Merck’s Investigational Ebola Vaccine Efficacious; Study is Continuing Stock Update: Merck & Co Inc (NYSE:MRK) – Merck and Samsung Bioepis Announce Pivotal Phase 3 Studies for Investigational Biosimilars SB4, Enbrel (Etanercept), and SB2, Remicade (Infliximab), Met Primary Endpoints Stock Update: Merck & Co Inc (NYSE:MRK) – Merck Announces Results from C-SURFER Phase 2/3 Study of Investigational Chronic Hepatitis C Therapy Grazoprevir/Elbasvir in Patients with Advanced Chronic Kidney Disease